The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Subscribe To Our Newsletter & Stay Updated
